Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Non-Current Debt (2017 - 2021)

Sunshine Biopharma's Non-Current Debt history spans 5 years, with the latest figure at $1.9 million for Q4 2021.

  • For Q4 2021, Non-Current Debt rose 100.21% year-over-year to $1.9 million; the TTM value through Dec 2021 reached $1.9 million, up 100.21%, while the annual FY2021 figure was $1.9 million, 100.21% up from the prior year.
  • Non-Current Debt reached $1.9 million in Q4 2021 per SBFM's latest filing, down from $3.2 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $3.2 million in Q3 2021 to a low of $63234.0 in Q2 2020.
  • Average Non-Current Debt over 5 years is $1.1 million, with a median of $357552.0 recorded in 2020.
  • The largest YoY upside for Non-Current Debt was 3148.59% in 2021 against a maximum downside of 100.21% in 2021.
  • A 5-year view of Non-Current Debt shows it stood at $79710.0 in 2017, then surged by 263.63% to $289847.0 in 2018, then dropped by 0.01% to $289825.0 in 2019, then surged by 227.44% to $949006.0 in 2020, then skyrocketed by 100.21% to $1.9 million in 2021.
  • Per Business Quant, the three most recent readings for SBFM's Non-Current Debt are $1.9 million (Q4 2021), $3.2 million (Q3 2021), and $2.1 million (Q2 2021).